Summary
The antihypertensive efficacy and endocrine profile of the new antihypertensive agent, Ro 12-4713, were evaluated in 23 patients (17 men and 6 women) with moderate to severe arterial hypertension. Following addition of Ro 12-4713 to pre-existing therapy with diuretics and beta-blockers or sympatholytics, blood pressure in most of the patients was normalized within one month by a daily dose of 60 to 120 mg. Heart rate was only slightly increased. Orthostatic hypotension was not observed. Weight gain or oedema formation occurred in 14 patients within the first four weeks, but could be controlled satisfactorily by intensified diuretic therapy. Increased hair growth occurred in most of the patients. After a mean duration of treatment of 2.8 months, plasma volume and plasma and urine sodium were unaltered, and plasma potassium was slightly decreased. Plasma renin activity was doubled, whereas plasma aldosterone concentrations were unaltered. Plasma norepinephrine levels were high before and increased only slightly during chronic Ro 12-4713 treatment, whereas urinary norepinephrine excretion was unchanged. Plasma and urinary epinephrine were unaltered by Ro 12-4713. Ro 12-4713 appears to be a potent vasodilator for the combination treatment of hypertension in men.
Similar content being viewed by others
References
Meier A, Weidmann P, Glück Z, Keusch GW, Grimm M, Minder I, Reubi FC (1980) Comparison of oral diazoxide and minoxidil in refractory hypertension. Klin Wochenschr 58: 681–688
Keusch GW, Weidmann P, Campese V, Lee DBN, Upham AT, Massry SG (1978) Minoxidil therapy in refractory hypertension. Analysis of 155 patients. Nephron 21: 1–15
Gerold M, Eigenmann R, Hefti F, Daum A, Häusler G (1981) Cardiovascular effects of a novel vaso-active antihypertensive agent, Ro 12-4713. J Pharmacol Exp Ther 216: 624–633
Grimm M, Weidmann P, Meier A, Ziegler WH, Reubi FC (1981) Acute effects of a new vasodilator, Ro 12-4713, on blood pressure, plasma renin activity, aldosterone and catecholamine levels, and renal function in hypertensive and normal subjects. Eur J Clin Pharmacol 20 (in press)
Sealey JE, Gerten-Banes J, Laragh JH (1972) The renin system: Variations in man measured by radioimmunoassay or bioassay. Kidney Int 1: 240–253
Vetter W, Vetter H, Siegenthaler W (1973) Radioimmunoassay for aldosterone without chromatography: II. Determination of plasma aldosterone. Acta Endocrinol (Copenh) 74: 558–567
Bertler A, Carlsson A, Rosengren E (1958) A method for the fluorometric determination of adrenaline and noradrenaline in tissues. Acta Physiol Scand 44: 273–292
Da Prada M, Zürcher G (1976) Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range. Life Sci 19: 1161–1174
Weidmann P, Beretta-Piccoli C, Ziegler WH, Keusch GW, Glück Z, Reubi FC (1978) Age versus urinary sodium for judging renin, aldosterone, and catecholamine levels: Studies in normal subjects and patients with essential hypertension. Kidney Int 14: 619–628
Veall N, Vetter H (1958). Radioisotope techniques in clinical research and diagnosis. Butterworth, London p 189
Grimm CE, Luft FC, Grim CM, Klotman PE, Van Huysse J, Weinberger MH (1979) Rapid pressure control with minoxidil. Acute and chronic effects in blood pressure, sodium excretion, and renin-aldosterone system. Arch Intern Med 139: 529–533
Masuyama Y, Nishimura T, Nishio I, Kuchii M (1979) Noradrenaline clearance in hypertensive patients with various degrees of renal function. Clin Sci 57: 213s–215s
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grimm, M., Weidmann, P., Meier, A. et al. Chronic treatment with the new potent vasodilator Ro 12-4713 in moderate to severe hypertension: Effects on blood pressure, endocrine function, sodium and plasma volume. Eur J Clin Pharmacol 20, 79–84 (1981). https://doi.org/10.1007/BF00607141
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607141